Skip to content

Treatment of sleeplessness with Unani medicine

Therapeutic evaluation of Tukhm-e-Khurfa Siyah (Portulaca oleracea L.) and Tukhm-e-Kahu (Lactuca sativa L.) in generalized anxiety disorder (GAD) associated insomnia. - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/07/091421
Enrollment
40
Registered
2025-07-22
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G470- Insomnia

Interventions

Intervention1: Tukhm-e-Khurfa (Portulaca oleracea L.): 3 gram powder of the drug in two equally divided doses orally, morning and evening for 28 days Control Intervention1: Tukhm-e-Kahu (Lactuca Sativ

Sponsors

Jamia Hamdard University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients fulfilling Diagnostic Criteria of insomnia disorder and generalised anxiety disorder as per DSM 5-TR 2.Patients scoring 14+ on insomnia severity index (Clinical and Severe insomnia), and 3.Patients scoring upto 10 on GAD-7 scale (mild- moderate anxiety) 4.Mentally stable patients 5.Patient of all genders 6.Patients in age group of 18-65 years

Exclusion criteria

Exclusion criteria: 1.Pregnant and lactating women 2.Previous history of known psychiatric disorders except generalised anxiety disorder 3.Night shift workers 4.Excessive consumption of beverages having caffeine (tea, coffee or cola >5 cups or glasses per day) 5.Any concomitant medication for insomnia or anxiety 6.Patients having past history of seizures or epilepsy 7.Terminally ill, having any malignancy or chronic progressive medical or surgical condition 8.Patients having uncontrolled diabetes mellitus or hypertension 9.Patients of hyperthyroidism 10.Patients suffering from itching conditions like scabies, eczema and psoriasis.

Design outcomes

Primary

MeasureTime frame
1.Improvement in Insomnia Severity Score using Insomnia Severity Index (ISI) questionnaire. 2. Improvement in Generalised anxiety disorder score using GAD-7 questionnaire.Timepoint: Baseline, 4 weeks

Secondary

MeasureTime frame
improvement in clinical symptoms 1. mood uplifting 2. energy 3. public dealingTimepoint: Baseline, 4 weeks

Countries

India

Contacts

Public ContactSAMREEN SAYYED

Jamia Hamdard University

drmdwasiakhtar@jamiahamdard.ac.in9027570265

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026